Lewy Body Disease Pipeline Appears Promising With 10+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

DelveInsight's, "Lewy Body Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Lewy Body Disease pipeline landscape. It covers the Lewy Body Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Lewy Body Disease Pipeline Report to explore emerging therapies, key Lewy Body Disease Companies, and future Lewy Body Disease treatment landscapes @ Lewy Body Disease Pipeline Outlook Report- https://www.delveinsight.com/sample-request/lewy-body-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Lewy Body Disease Pipeline Report
• In July 2025, EIP Pharma Inc. announced a study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
• In July 2025, ACADIA Pharmaceuticals Inc. conducted a Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP).
• DelveInsight's Lewy Body Disease pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Lewy Body Disease treatment.
• The leading Lewy Body Disease Companies such as Athira Pharma, Eli Lilly and Company, Cognition Therapeutics, Seelos Therapeutics, NLS Pharmaceutics and others.
• Promising Lewy Body Disease Pipeline Therapies such as Pimavanserin 20 mg, NYX-458, DatSCAN, 18F-AV-133, Nelotanserin, RVT-101 35 mg, Memantine, and others.

Discover how the Lewy Body Disease treatment paradigm is evolving. Access DelveInsight's in-depth Lewy Body Disease Pipeline Analysis for a closer look at promising breakthroughs @ Lewy Body Disease Clinical Trials and Studies- https://www.delveinsight.com/sample-request/lewy-body-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Lewy Body Disease Emerging Drugs Profile
• LY3154207: Eli Lilly and Company
Mevidalen (LY3154207) is a selective and orally active D1-positive allosteric modulator with >1000-fold selectivity for the human D1 receptor over other tested targets. Mevidalen increases the extracellular level of acetylcholine in the prefrontal cortex and enhances the affinity of dopamine for the D1 receptor. This amplifies the responses to endogenous and exogenous dopamine, which may improve motor and cognitive symptoms of Parkinson Disease and Lewy body dementias as well as sleepiness, mood, and apathy.

• CT1812: Cognition Therapeutics
Zervimesine (CT1812) is an investigational oral, once-daily pill being developed for the treatment of CNS diseases such as Alzheimer's disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain - Aβ and ɑ-synuclein. As these proteins bind to neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person's ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. If zervimesine can interrupt the toxic effects of these proteins, it may be able to slow progression of disease and improve the lives of those suffering from Alzheimer's and DLB.

• Neflamapimod: CervoMed
Neflamapimod is an investigational, orally administered small molecule brain penetrant drug that inhibits alpha isoform of the p38MAP kinase. In preclinical studies, neflamapimod reversed synaptic dysfunction, including and particularly within the part of the brain most impacted in DLB - the basal forebrain cholinergic system. In Phase I and Phase II clinical studies involving more than 400 participants, neflamapimod has been shown to be generally well tolerated. Results from the AscenD-LB Phase IIa clinical study demonstrated that neflamapimod improved dementia severity (assessed by CDR-SB) compared to placebo and improved functional mobility (assessed by TUG test) compared to placebo. At the highest dose evaluated, neflamapimod also improved results on a cognitive test battery. The treatment response in AscenD-LB in the participants who did not have AD co-pathology (as assessed by a blood biomarker, plasma ptau181) was substantial (effect size > 0.7) and greater than the overall study population. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Lewy body disease.

The Lewy Body Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Lewy Body Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lewy Body Disease Treatment.
• Lewy Body Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Lewy Body Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lewy Body Disease market.

Get a detailed analysis of the latest innovations in the Lewy Body Disease pipeline. Explore DelveInsight's expert-driven report today! @ Lewy Body Disease Unmet Needs- https://www.delveinsight.com/sample-request/lewy-body-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Lewy Body Disease Companies
Athira Pharma, Eli Lilly and Company, Cognition Therapeutics, Seelos Therapeutics, NLS Pharmaceutics and others.

Lewy Body Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Lewy Body Disease Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight's latest report to gain strategic insights into upcoming Lewy Body Disease Therapies and key Lewy Body Disease Developments @ Lewy Body Disease Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/lewy-body-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Lewy Body Disease Pipeline Report
• Coverage- Global
• Lewy Body Disease Companies- Athira Pharma, Eli Lilly and Company, Cognition Therapeutics, Seelos Therapeutics, NLS Pharmaceutics and others.
• Lewy Body Disease Pipeline Therapies- Pimavanserin 20 mg, NYX-458, DatSCAN, 18F-AV-133, Nelotanserin, RVT-101 35 mg, Memantine, and others.
• Lewy Body Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Lewy Body Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Lewy Body Disease drug development? Find out in DelveInsight's exclusive Lewy Body Disease Pipeline Report-access it now! @ Lewy Body Disease Emerging Drugs and Major Companies- https://www.delveinsight.com/sample-request/lewy-body-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Lewy Body Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Lewy Body Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Neflamapimod: CervoMed
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Lewy Body Disease - Collaborations Assessment- Licensing / Partnering / Funding
20. Lewy Body Disease - Unmet Needs
21. Lewy Body Disease - Market Drivers and Barriers
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.